As a proof of concept, we demonstrate that a small-molecule inhibitor rationally designed against MBNL1 can preferentially kill MLL-rearranged leukemia cells while sparing normal CD34+ hematopoietic stem/progenitor cells. This evidence concerns the gene MBNL1 and leukemia.